2025 Half Year Media Release
Filed with ASX · · 7 pages · English
Summary by 6ix AI
The company reported a notable increase in underlying EBITDA and cash flow from continuing operations, reflecting a strong operational performance. Additionally, Mayne Pharma announced a scheme implementation deed with Cosette Pharmaceuticals for a proposed acquisition, valuing the company at a premium to its recent share price. The outlook remains positive, with expectations for continued revenue growth across its Women’s Health and Dermatology segments in the second half of the fiscal year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
Mayne Pharma Group Ltd. on 6ix
In the deck
Story so far
Earlier from Mayne Pharma
- Mayne Pharma enters Scheme Implementation Deed with Cosette
- Mayne Pharma market update
- 2024 AGM presentation and business update
- Mayne Pharma reports FY24 financial results
- 2024 Full Year Results Investor Presentation
Later from Mayne Pharma
- 2025 Half Year Investor Presentation
- Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
- Response to ASX Query
- Pause in Trade
- Response to ASX Price Query
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma